Peer-reviewed veterinary case report
Testing six leishmaniasis vaccines with different adjuvants in dogs
By Poot, J et al.·Published in Vaccine·2009·Intervet International B.V., Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
- Species:
- dog
Plain-English summary
A group of dogs was vaccinated with six different experimental vaccines to see if they could protect against leishmaniasis, a disease caused by a parasite. While the vaccines were found to be safe and triggered some immune responses, they did not effectively protect the dogs from the disease after being exposed to the parasite. The study suggests that a previously used vaccine, live BCG, might still offer some protection, but it is not safe for commercial use in dogs. Overall, the new vaccine candidates did not provide the hoped-for defense against leishmaniasis.
People also search for: dog leishmaniasis vaccine · canine leishmaniasis treatment · why is my dog sick after vaccination
Abstract
Chimerical protein "Q", composed of antigenic ribosomal and histone sequences, in combination with live BCG is a promising canine leishmaniasis vaccine candidate; one of the few vaccine candidates that have been tested successfully in dogs. Unfortunately, live BCG is not an appropriate adjuvant for commercial application due to safety problems in dogs. In order to find a safe adjuvant with similar efficacy to live BCG, muramyl dipeptide, aluminium hydroxide, Matrix C and killed Propionibacterium acnes in combination with either E. coli- or baculovirus-produced recombinant JPCM5_Q protein were tested. Groups of five or seven dogs were vaccinated with six different adjuvant-antigen combinations and challenged with a high dose intravenous injection of Leishmania infantum JPC strain promastigotes. All candidate vaccines proved to be safe, and both humoral and cellular responses to the recombinant proteins were detected at the end of the prime-boost vaccination scheme. However, clinical and parasitological data obtained during the 10 month follow-up period indicated that protection was not induced by either of the six candidate vaccines. Although no direct evidence was obtained, our data suggest that live BCG may have a significant protective effect against challenge with L. infantum in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19500553/